Accueil>>[Leu31,Pro34] Neuropeptide Y (human) (trifluoroacetate salt)

[Leu31,Pro34] Neuropeptide Y (human) (trifluoroacetate salt) (Synonyms: Leu31,Pro34 NPY)

Catalog No.GC41744

[Leu31,Pro34] Neuropeptide Y (NPY) is an agonist of the NPY receptors Y1 and Y5 with Ki values of 0.11 and 0.17 nM, respectively, for human and 0.08 and 0.18 nM, respectively, for rhesus monkey receptors.

Products are for research use only. Not for human use. We do not sell to patients.

[Leu31,Pro34] Neuropeptide Y (human) (trifluoroacetate salt) Chemical Structure

Taille Prix Stock Qté
500μg
214,00 $US
En stock
1mg
408,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

[Leu31,Pro34] Neuropeptide Y (NPY) is an agonist of the NPY receptors Y1 and Y5 with Ki values of 0.11 and 0.17 nM, respectively, for human and 0.08 and 0.18 nM, respectively, for rhesus monkey receptors. It reduces forskolin-induced cAMP accumulation in L-M(TK-) cells expressing human and rat Y4 receptors (EC50s = 29.5 and 2.95 nM, respectively). It also binds to rhesus monkey Y2 and mouse Y6 receptors (Kis = 410 and 9.7 nM, respectively). In vitro, [Leu31,Pro34] NPY increases cellular protein mass by 25% in rat ventricular cardiomyocytes when used at a concentration of 10 nM. In vivo, [Leu31,Pro34] NPY (0.7-7 nmol, i.c.v.) increases food intake in rats.

Avis

Review for [Leu31,Pro34] Neuropeptide Y (human) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for [Leu31,Pro34] Neuropeptide Y (human) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.